Dr. Alison Stopeck, MD - Stony Brook, NY - Hematology Oncology

Dr. Alison Stopeck, MD - Stony Brook, NY - Hematology Oncology
Loading Complete
Alison Stopeck
MD
Hematology Oncology
Accepting New Patients
Video Visit
Need help scheduling? Call
631-638-1000
Highlights
Languages
Gender
Female
About Alison Stopeck
About
Alison Stopeck, MD, is the Chief of the Division of Hematology/Oncology and a Professor of Medicine at Stony Brook University College of Medicine.  She is also the Associate Director for Clinical and Translational Research for the Stony Brook Cancer Center.  After receiving her bachelor’s degree from Brown University in Providence, Rhode Island, Dr. Stopeck completed her medical degree at Columbia University College of Physicians and Surgeons in New York City.  She remained at Columbia for a residency in internal medicine and then completed a fellowship in hematology/oncology at Cornell University Medical College.  She is a native Long Islander and moved to the Stony Brook Cancer Center in September 2014 where she focuses on breast cancer treatment and clinical trials.
Dr. Stopeck has authored or co-authored over 200 book chapters, refereed journal articles, abstracts, and editorials.  She is an associate editor for the American Journal of Medicine heading the hematology/oncology section.
She has been named as one of the Best Doctors in America, and America’s Top Doctors for Cancer.  She is a member of several professional organizations, including the American Association for Cancer Research and the American Society of Clinical Oncology.  Her breast cancer research interests include novel therapies, understanding the tumor microenvironment, and developing predictors of antitumor therapies or chemopreventive agents.
Academic Title
Professor of Medicine
Publications
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.
von Moos R | Body JJ | Egerdie B | Stopeck A | Brown J | Fallowfield L | Patrick DL | Cleeland C | Damyanov D | Palazzo FS | Marx G | Zhou Y | Braun A | Balakumaran A | Qian Y
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2016 Mar
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
Brown-Glaberman U | Marron M | Chalasani P | Livingston R | Iannone M | Specht J | Stopeck AT
Disease markers
2016
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.
Lipton A | Fizazi K | Stopeck AT | Henry DH | Smith MR | Shore N | Martin M | Vadhan-Raj S | Brown JE | Richardson GE | Saad F | Yardley DA | Zhou K | Balakumaran A | Braun A
European journal of cancer (Oxford, England : 1990)
2016 Jan
Pathophysiology of tumour-induced microangiopathic haemolytic anaemia.
Chalasani P | Segar JM | Marron M | Stopeck A
BMJ case reports
2016
A maximum-likelihood method to estimate a single ADC value of lesions using diffusion MRI.
Jha AK | Rodriguez JJ | Stopeck AT
Magnetic resonance in medicine
2016 Jan 7
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT | Fizazi K | Body JJ | Brown JE | Carducci M | Diel I | Fujiwara Y | Martin M | Paterson A | Tonkin K | Shore N | Sieber P | Kueppers F | Karsh L | Yardley D | Wang H | Maniar T | Arellano J | Braun A
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2016 Jan
Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series.
Chahal J | Stopeck A | Clarke K | Livingston RB | Chalasani P
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2015 Sep
Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ | Bone HG | de Boer RH | Stopeck A | Van Poznak C | Damiao R | Fizazi K | Henry DH | Ibrahim T | Lipton A | Saad F | Shore N | Takano T | Shaywitz AJ | Wang H | Bracco OL | Braun A | Kostenuik PJ
European journal of cancer (Oxford, England : 1990)
2015 Sep
A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.
Chalasani P | Marron M | Roe D | Clarke K | Iannone M | Livingston RB | Shan JS | Stopeck AT
Cancer medicine
2015 Jul
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
Diel IJ | Body JJ | Stopeck AT | Vadhan-Raj S | Spencer A | Steger G | von Moos R | Goldwasser F | Feng A | Braun A
European journal of cancer (Oxford, England : 1990)
2015 Jul
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
Yardley DA | Weaver R | Melisko ME | Saleh MN | Arena FP | Forero A | Cigler T | Stopeck A | Citrin D | Oliff I | Bechhold R | Loutfi R | Garcia AA | Cruickshank S | Crowley E | Green J | Hawthorne T | Yellin MJ | Davis TA | Vahdat LT
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2015 May 10
Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.
Chen LQ | Howison CM | Spier C | Stopeck AT | Malm SW | Pagel MD | Baker AF
Leukemia & lymphoma
2015 May
Automated breast segmentation of fat and water MR images using dynamic programming.
Rosado-Toro JA | Barr T | Galons JP | Marron MT | Stopeck A | Thomson C | Thompson P | Carroll D | Wolf E | Altbach MI | Rodriguez JJ
Academic radiology
2015 Feb
Diffusion MRI with Semi-Automated Segmentation Can Serve as a Restricted Predictive Biomarker of the Therapeutic Response of Liver Metastasis.
Stephen RM | Jha AK | Roe DJ | Trouard TP | Galons JP | Kupinski MA | Frey G | Cui H | Squire S | Pagel MD | Rodriguez JJ | Gillies RJ | Stopeck AT
Magnetic resonance imaging
2015 Dec
Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT | Fizazi K | Body JJ | Brown JE | Carducci M | Diel I | Fujiwara Y | Martin M | Paterson A | Tonkin K | Shore N | Sieber P | Kueppers F | Karsh L | Yardley D | Wang H | Maniar T | Arellano J | Braun A
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2015 Oct 19
Isolation of viable cancer cells in antibody-functionalized microfluidic devices.
Zheng X | Jiang L | Schroeder J | Stopeck A | Zohar Y
Biomicrofluidics
2014 Mar
A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Chalasani P | Stopeck A | Clarke K | Livingston R
The oncologist
2014 Nov
Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases.
Matza LS | Cong Z | Chung K | Stopeck A | Tonkin K | Brown J | Braun A | Van Brunt K | McDaniel K
Patient preference and adherence
2013
Impact of denosumab on bone mass in cancer patients.
Brown-Glaberman U | Stopeck AT
Clinical pharmacology : advances and applications
2013
Reply to Araki et al.
Lipton A | Fizazi K | Stopeck AT | Henry DH | Braun AH
European journal of cancer (Oxford, England : 1990)
2013 Jun
Authors' response to letter to the editor.
Stopeck A | Henry D | Dansey R | Qian Y | Cong Z | Arellano J
Journal of medical economics
2013
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
Cleeland CS | Body JJ | Stopeck A | von Moos R | Fallowfield L | Mathias SD | Patrick DL | Clemons M | Tonkin K | Masuda N | Lipton A | de Boer R | Salvagni S | Oliveira CT | Qian Y | Jiang Q | Dansey R | Braun A | Chung K
Cancer
2013 Feb 15
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
von Moos R | Body JJ | Egerdie B | Stopeck A | Brown JE | Damyanov D | Fallowfield LJ | Marx G | Cleeland CS | Patrick DL | Palazzo FG | Qian Y | Braun A | Chung K
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2013 Dec
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
Martin M | Bell R | Bourgeois H | Brufsky A | Diel I | Eniu A | Fallowfield L | Fujiwara Y | Jassem J | Paterson AH | Ritchie D | Steger GG | Stopeck A | Vogel C | Fan M | Jiang Q | Chung K | Dansey R | Braun A
Clinical cancer research : an official journal of the American Association for Cancer Research
2012 Sep 1
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
Stopeck AT | Unger JM | Rimsza LM | LeBlanc M | Farnsworth B | Iannone M | Glenn MJ | Fisher RI | Miller TP
Blood
2012 Aug 9
Task-based evaluation of segmentation algorithms for diffusion-weighted MRI without using a gold standard.
Jha AK | Kupinski MA | Rodriguez JJ | Stephen RM | Stopeck AT
Physics in medicine and biology
2012 Jul 7
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
Rugo HS | Chien AJ | Franco SX | Stopeck AT | Glencer A | Lahiri S | Arbushites MC | Scott J | Park JW | Hudis C | Nulsen B | Dickler MN
Breast cancer research and treatment
2012 Jul
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A | Rader M | Henry D | Danese M | Halperin M | Cong Z | Qian Y | Dansey R | Chung K
Journal of medical economics
2012
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
Saad F | Brown JE | Van Poznak C | Ibrahim T | Stemmer SM | Stopeck AT | Diel IJ | Takahashi S | Shore N | Henry DH | Barrios CH | Facon T | Senecal F | Fizazi K | Zhou L | Daniels A | Carriere P | Dansey R
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2012 May
Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.
Brown-Glaberman U | Stopeck AT
Biologics : targets & therapy
2012
Prevalence of depression in adults with haemophilia.
Iannone M | Pennick L | Tom A | Cui H | Gilbert M | Weihs K | Stopeck AT
Haemophilia : the official journal of the World Federation of Hemophilia
2012 Nov
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
Lipton A | Fizazi K | Stopeck AT | Henry DH | Brown JE | Yardley DA | Richardson GE | Siena S | Maroto P | Clemens M | Bilynskyy B | Charu V | Beuzeboc P | Rader M | Viniegra M | Saad F | Ke C | Braun A | Jun S
European journal of cancer (Oxford, England : 1990)
2012 Nov
The role of targeted therapy and biomarkers in breast cancer treatment.
Stopeck AT | Brown-Glaberman U | Wong HY | Park BH | Barnato SE | Gradishar WJ | Hudis CA | Rugo HS
Clinical & experimental metastasis
2012 Oct
How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?
Gralow JR | Lipton A | Stopeck AT
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2011 Sep 10
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
Modi S | Stopeck A | Linden H | Solit D | Chandarlapaty S | Rosen N | D'Andrea G | Dickler M | Moynahan ME | Sugarman S | Ma W | Patil S | Norton L | Hannah AL | Hudis C
Clinical cancer research : an official journal of the American Association for Cancer Research
2011 Aug 1
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Rugo HS | Stopeck AT | Joy AA | Chan S | Verma S | Lluch A | Liau KF | Kim S | Bycott P | Rosbrook B | Bair AH | Soulieres D
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2011 Jun 20
Systemic treatment of early breast cancer--a biological perspective.
Greenberg S | Stopeck A | Rugo HS
Journal of surgical oncology
2011 May 1
Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.
Gerber DE | Stopeck AT | Wong L | Rosen LS | Thorpe PE | Shan JS | Ibrahim NK
Clinical cancer research : an official journal of the American Association for Cancer Research
2011 Nov 1
Caring for the breast cancer survivor: a guide for primary care physicians.
Chalasani P | Downey L | Stopeck AT
The American journal of medicine
2010 Jun
A Clustering Algorithm for Liver Lesion Segmentation of Diffusion-Weighted MR Images.
Jha AK | Rodriguez JJ | Stephen RM | Stopeck AT
Proceedings / IEEE Southwest Symposium on Image Analysis and Interpretation. IEEE Southwest Symposium on Image Analysis and Interpretation
2010 May 23
Denosumab findings in metastatic breast cancer.
Stopeck A
Clinical advances in hematology & oncology : H&O
2010 Mar
Evaluating segmentation algorithms for diffusion-weighted MR images: a task-based approach.
Jha AK | Kupinski MA | Rodriguez JJ | Stephen RM | Stopeck AT
Proceedings of SPIE--the International Society for Optical Engineering
2010 Feb 27
A case of metaplastic carcinoma of the breast responsive to chemotherapy with Ifosfamide and Etoposide: improved antitumor response by targeting sarcomatous features.
Brown-Glaberman U | Graham A | Stopeck A
The breast journal
2010 Nov-Dec
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT | Lipton A | Body JJ | Steger GG | Tonkin K | de Boer RH | Lichinitser M | Fujiwara Y | Yardley DA | Viniegra M | Fan M | Jiang Q | Dansey R | Jun S | Braun A
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010 Dec 10
Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs. reduced carbohydrate diets.
Thomson CA | Stopeck AT | Bea JW | Cussler E | Nardi E | Frey G | Thompson PA
Nutrition and cancer
2010
Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial.
Thompson PA | Hsu CH | Green S | Stopeck AT | Johnson K | Alberts DS | Chow HH
Cancer prevention research (Philadelphia, Pa.)
2010 Jan
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.
Stopeck AT | Unger JM | Rimsza LM | Bellamy WT | Iannone M | Persky DO | Leblanc M | Fisher RI | Miller TP
Leukemia & lymphoma
2009 May
Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia.
Gerstner G | Damiano ML | Tom A | Worman C | Schultz W | Recht M | Stopeck AT
Haemophilia : the official journal of the World Federation of Hemophilia
2009 Mar
Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy.
Thomson CA | Thompson PA | Wright-Bea J | Nardi E | Frey GR | Stopeck A
Journal of women's health (2002)
2009 Dec
A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer.
Gordon MS | Mendelson D | Carr R | Knight RA | Humerickhouse RA | Iannone M | Stopeck AT
Cancer
2008 Dec 15
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
DeAngelo DJ | Yu D | Johnson JL | Coutre SE | Stone RM | Stopeck AT | Gockerman JP | Mitchell BS | Appelbaum FR | Larson RA
Blood
2007 Jun 15
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Modi S | Stopeck AT | Gordon MS | Mendelson D | Solit DB | Bagatell R | Ma W | Wheler J | Rosen N | Norton L | Cropp GF | Johnson RG | Hannah AL | Hudis CA
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2007 Dec 1
Diagnosing and treating breast cancer in elderly women: a call for improved understanding.
Downey L | Livingston R | Stopeck A
Journal of the American Geriatrics Society
2007 Oct
What happened to the coxibs on the way to the cardiologist?
Alberts DS | Potter JD | Martinez ME | Hess LM | Stopeck A | Lance P
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
2005 Mar
Women's health: the struggle to restore hormonal balance.
Stopeck AT
The American journal of medicine
2005 Nov
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
O'Farrell AM | Yuen HA | Smolich B | Hannah AL | Louie SG | Hong W | Stopeck AT | Silverman LR | Lancet JE | Karp JE | Albitar M | Cherrington JM | Giles FJ
Leukemia research
2004 Jul
Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy.
Theilmann RJ | Borders R | Trouard TP | Xia G | Outwater E | Ranger-Moore J | Gillies RJ | Stopeck A
Neoplasia (New York, N.Y.)
2004 Nov-Dec
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Zangari M | Anaissie E | Stopeck A | Morimoto A | Tan N | Lancet J | Cooper M | Hannah A | Garcia-Manero G | Faderl S | Kantarjian H | Cherrington J | Albitar M | Giles FJ
Clinical cancer research : an official journal of the American Association for Cancer Research
2004 Jan 1
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Giles FJ | Stopeck AT | Silverman LR | Lancet JE | Cooper MA | Hannah AL | Cherrington JM | O'Farrell AM | Yuen HA | Louie SG | Hong W | Cortes JE | Verstovsek S | Albitar M | O'Brien SM | Kantarjian HM | Karp JE
Blood
2003 Aug 1
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Giles FJ | Cooper MA | Silverman L | Karp JE | Lancet JE | Zangari M | Shami PJ | Khan KD | Hannah AL | Cherrington JM | Thomas DA | Garcia-Manero G | Albitar M | Kantarjian HM | Stopeck AT
Cancer
2003 Apr 15
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Stopeck A | Sheldon M | Vahedian M | Cropp G | Gosalia R | Hannah A
Clinical cancer research : an official journal of the American Association for Cancer Research
2002 Sep
Radial fast spin-echo method for T2-weighted imaging and T2 mapping of the liver.
Altbach MI | Outwater EK | Trouard TP | Krupinski EA | Theilmann RJ | Stopeck AT | Kono M | Gmitro AF
Journal of magnetic resonance imaging : JMRI
2002 Aug
Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast.
Coronella JA | Spier C | Welch M | Trevor KT | Stopeck AT | Villar H | Hersh EM
Journal of immunology (Baltimore, Md. : 1950)
2002 Aug 15
Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
Stopeck AT | Jones A | Hersh EM | Thompson JA | Finucane DM | Gutheil JC | Gonzalez R
Clinical cancer research : an official journal of the American Association for Cancer Research
2001 Aug
Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft.
Clark PR | Stopeck AT | Parker SE | Hersh EM
Cellular immunology
2000 Sep 15
Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA.
Clark PR | Stopeck AT | Ferrari M | Parker SE | Hersh EM
Cancer gene therapy
2000 Jun
Construction of new amplifier expression vectors for high levels of IL-2 gene expression.
Tsang TC | Brailey JL | Vasanwala FH | Wu RS | Liu F | Clark PR | Meade-Tollin L | Luznick L | Stopeck AT | Akporiaye ET | Harris DT
International journal of molecular medicine
2000 Mar
Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.
Stopeck AT | Gessner A | Miller TP | Hersh EM | Johnson CS | Cui H | Frutiger Y | Grogan TM
Clinical cancer research : an official journal of the American Association for Cancer Research
2000 Oct
Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
Galanis E | Hersh EM | Stopeck AT | Gonzalez R | Burch P | Spier C | Akporiaye ET | Rinehart JJ | Edmonson J | Sobol RE | Forscher C | Sondak VK | Lewis BD | Unger EC | O'Driscoll M | Selk L | Rubin J
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
1999 Oct
Polycations and cationic lipids enhance adenovirus transduction and transgene expression in tumor cells.
Clark PR | Stopeck AT | Brailey JL | Wang Q | McArthur J | Finer MH | Hersh EM
Cancer gene therapy
1999 Sep-Oct
Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes.
Stopeck AT | Hersh EM | Brailey JL | Clark PR | Norman J | Parker SE
Cancer gene therapy
1998 Mar-Apr
Human gene therapy for melanoma: CT-guided interstitial injection.
Waddill W 3rd | Wright W Jr | Unger E | Stopeck A | Akporiaye E | Harris D | Grogan T | Schluter S | Hersh E | Stahl S
AJR. American journal of roentgenology
1997 Jul
Transfer and expression of the interferon gamma gene in human endothelial cells inhibits vascular smooth muscle cell growth in vitro.
Stopeck AT | Vahedian M | Williams SK
Cell transplantation
1997 Jan-Feb
Advances in the biological therapy and gene therapy of malignant disease.
Hersh EM | Stopeck AT
Clinical cancer research : an official journal of the American Association for Cancer Research
1997 Dec
Recent advances in the treatment of malignant melanoma with gene therapy.
Hersh EM | Stopeck AT
Molecular medicine (Cambridge, Mass.)
1997 Oct
Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma.
Stopeck AT | Hersh EM | Akporiaye ET | Harris DT | Grogan T | Unger E | Warneke J | Schluter SF | Stahl S
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
1997 Jan
Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo.
Parker SE | Khatibi S | Margalith M | Anderson D | Yankauckas M | Gromkowski SH | Latimer T | Lew D | Marquet M | Manthorpe M | Hobart P | Hersh E | Stopeck AT | Norman J
Cancer gene therapy
1996 May-Jun
Interferon gamma (IFNgamma) gene transfer of an EMT6 tumor that is poorly responsive to IFNgamma stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC.
Panelli MC | Wang E | Shen S | Schluter SF | Bernstein RM | Hersh EM | Stopeck A | Gangavalli R | Barber J | Jolly D | Akporiaye ET
Cancer immunology, immunotherapy : CII
1996 Feb
Phase I study of immunotherapy of malignant melanoma by direct gene transfer.
Hersh EM | Akporiaye E | Harris D | Stopeck AT | Unger EC | Warneke JA | Kradjian SA
Human gene therapy
1994 Nov
Locations
Stony Brook Cancer Center - Medical Oncology - Breast Care Center
Lauterbur Drive
Stony Brook
NY
11794
Get Directions
phone:
631-722-2623
fax:
631-638-3526
The Phillips Family Cancer Center - Medical Oncology Provider
740 County Road 39A
Southampton
NY
11968
Get Directions
phone:
631-638-7702
fax:
631-638-7327
Expertise
Education
Fellowship:
Weill Cornell Medical College
IM-Hematology/Oncol
1991
Residency:
Columbia/NY Presbyterian Medical Center
Internal Medicine
1988
Medical School:
Columbia University College of Physicians and Surgeons
1985
Board Certifications
Medical Oncology:
American Board of Internal Medicine
1991
Internal Medicine:
American Board of Internal Medicine
1988
Insurance
Please contact the doctor's office directly to confirm acceptance of insurance.
Search plans
Start typing to search for insurances accepted
(Anthem) EMP HEALTH CHOICE HMO
(Anthem) EMP HEALTH CHOICE MEDICAID
(Anthem) EMP HEALTH CHOICE SR
(Emblem) HIP
AETNA
Affinity
Beech Street/Multiplan/PHCS
Centerlight (CCM)
CIGNA PPO
Fidelis
GHI / MEDICARE PLUS
GHI CBP
Health Smart WTC
HEALTHFIRST
Humana Military
MAGNACARE
MET EMPIRE
OXFORD
Partners Health Plan
Sedgwick
UNITED HEALTHCARE
Workers Compensation
Stony Brook
Medicine
Stony Brook
University Hospital
Stony Brook Children's
Hospital
Stony Brook Southampton
Hospital
Stony Brook
Eastern Long Island Hospital
Long Island State Veterans Home
Stony
Brook University
About Stony Brook Medicine
Legal/Disclaimer
Policy
Notice of Privacy Practices
Notice
of Non-Discrimination and Accessibility
Site Feedback
© Copyright 2025 Stony Brook Medicine